New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
10:00 EDTYRCW, WIN, UAL, TWTR, SEIC, STBA, RRTS, PRU, OSK, INVN, ICPT, IBTX, FSL, FNGN, FNFV, DSX, CHRW, RESI, AUOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AU Optronics (AUO) upgraded to Buy from Sell at Citigroup... Altisource Residential (RESI) upgraded to Outperform at Keefe Bruyette... C.H. Robinson (CHRW) upgraded to Neutral from Underperform at BofA/Merrill... Diana Shipping (DSX) upgraded to Buy from Hold at Stifel... Fidelity National Financial Ventures (FNFV) upgraded to Overweight from Equal Weight at Stephens... Financial Engines (FNGN) upgraded to Market Perform from Underperform at Raymond James... Freescale (FSL) upgraded to Equal Weight from Underweight at Morgan Stanley... Independent Bank (IBTX) upgraded to Outperform from Neutral at Macquarie... Intercept (ICPT) upgraded at Nomura... Internap (INAP) upgraded to Outperform from Market Perform at Cowen... InvenSense (INVN) upgraded to Buy from Hold at Ascendiant... Oshkosh (OSK) upgraded to Outperform from Neutral at RW Baird... Prudential (PRU) upgraded to Buy from Hold at Canaccord... Roadrunner (RRTS) upgraded to Outperform from Market Perform at Raymond James... S&T Bancorp (STBA) upgraded to Neutral from Sell at Guggenheim... SEI Investments (SEIC) upgraded at Oppenheimer... Twitter (TWTR) upgraded to Neutral from Sell at UBS... United Continental (UAL) upgraded to Overweight from Neutral at JPMorgan... Windstream (WIN) upgraded to Buy from Neutral at DA Davidson... YRC Worldwide (YRCW) upgraded to Market Perform from Underperform at Raymond James.
News For AUO;RESI;CHRW;DSX;FNFV;FNGN;FSL;IBTX;ICPT;INVN;OSK;PRU;RRTS;STBA;SEIC;TWTR;UAL;WIN;YRCW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 9, 2014
14:52 EDTFNGNCapital World Investors reports 10.1% passive stake in Financial Engines
Subscribe for More Information
14:01 EDTOSKOshkosh Defense segment aims to cut workforce by 250-300
Oshkosh announced that its Defense segment plans to reduce its workforce in Oshkosh by approximately 250-300 hourly positions in December. In addition, approximately 70 salaried positions will be eliminated with the majority being temporary employees, elimination of open positions and those retiring. With the reduction, Oshkosh will retain more than 1,800 Defense employees in Oshkosh, Wisconsin and key regional facilities around the world. The company said, "We continue to reshape our workforce as a result of significantly lower U.S. defense spending and dramatic reductions in military vehicle production. We have gone to great lengths to minimize and delay the impact of these changes on our Defense workforce. At the same time we are aggressively competing for future contracts including JLTV, MSVS and other international opportunities, which will serve as a catalyst for growth of the Defense business.
13:16 EDTTWTRTwitter November volatility elevated
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:20 EDTUALOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
07:52 EDTUALUnited Continental price target raised to $58 from $53 at UBS
UBS raised its price target on United Continental to $58 from $53 following guidance from the company. The firm expects the stock to trade higher on the update and reiterates its Buy rating on United Continental shares.
07:51 EDTUALUnited Continental lowers Q3 capex view to $470M-$490M, maintains FY view
United Continental expects between $470M-$490M of gross capital expenditures in Q3, which is below previous guidance. The difference versus prior guidance is primarily attributable to certain capital expenditures having shifted from Q3 to Q4. There is no impact to full-year 2014 capital expenditure guidance, the company said.
07:49 EDTUALUnited Continental reports Q3 PRASM up 3.5%-4%
Subscribe for More Information
07:24 EDTUALUnited Continental added to U.S. Focus List at Credit Suisse
Subscribe for More Information
October 8, 2014
20:03 EDTTWTRTwitter news head Vivian Schiller leaving company, Re/code reports
Subscribe for More Information
17:21 EDTUALUnited Continental reports September consolidated traffic down 0.2% y-o-y
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
11:26 EDTUALUnited Continental volatility increases as shares pull back
United Continental October weekly call option implied volatility is at 65, October is at 51, November is at 50, December is at 47; compared to its 26-week average of 43 according to Track Data, suggesting large price movement.
10:06 EDTCHRWStephens transportation analysts hold an analyst/industry conference call
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
06:00 EDTTWTRInstagram still most used social network for teens, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use